Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | IAPP | P10997 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403797 | 0.81 | MEN1 (0.48) | NPC1RAB9AAKR1B10AKR1B1HTT | |
| SCHEMBL6397688 | 0.81 | HDAC6 (0.46) | NPC1RAB9AAKR1B10AKR1B1HTT | |
| SCHEMBL6396968 | 0.75 | MEN1 (0.57) | CYP19A1ALDH1A1MAPK1 | |
| SCHEMBL6402277 | 0.75 | MEN1 (0.44) | AKR1B10AKR1B1CYP19A1 | |
| SCHEMBL6396379 | 0.70 | ACHE (0.47) | NPC1RAB9AAKR1B10AKR1B1HTT | |
| SCHEMBL6398689 | 0.70 | HDAC6 (0.46) | NPC1RAB9AAKR1B10AKR1B1 | |
| SCHEMBL7194165 | 0.69 | CYP19A1 (0.64) | CYP19A1CHRNA7 | |
| SCHEMBL6396371 | 0.69 | ESR1 (0.63) | NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL6396972 | 0.69 | ESR1 (0.46) | NPC1RAB9AHTTALDH1A1MAPK1 | |
| SCHEMBL7295307 | 0.68 | HTT (0.60) | NPC1RAB9AHTTCYP19A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787528-B2 | THERAPY FOR KIDNEY DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-09-07 | — | — | US | disclosed |
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | PEERCE BRIAN E (US) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | SLC10A2, SLC34A3, SLC34A1 | NPC1 292/4885PKM 2885/4885RAB9A 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.